Baylor Genetics

Baylor Genetics Baylor Genetics is a joint venture of H.U. Group Holdings and the #1 NIH-funded genetics program at

Baylor Genetics is founded in academics and driven by discovery; we are dedicated to delivering comprehensive answers to the toughest genetic questions.

We’re proud to share that Baylor Genetics is officially Great Place To Work® Certified™ for 2025!​ This recognition is b...
10/02/2025

We’re proud to share that Baylor Genetics is officially Great Place To Work® Certified™ for 2025!​ This recognition is based entirely on feedback from our employees, rating us 17 points above the U.S. company average.​

Our people are at the core of everything we do. This certification highlights our commitment to building a culture where employees feel valued, supported, and empowered to grow, while delivering innovative solutions that advance patient care.​

Thank you to our amazing team for making Baylor Genetics a community for collaboration and growth.​

Learn more: https://www.baylorgenetics.com/news/baylor-genetics-earns-2025-great-place-to-work-certification/

Join us this Breast Cancer Awareness Month to honor those impacted and highlight the importance of early detection. Did ...
10/01/2025

Join us this Breast Cancer Awareness Month to honor those impacted and highlight the importance of early detection.

Did you know that 5–10% of breast cancer is hereditary? While mutations in the BRCA1 and BRCA2 genes are the most common cause, additional genetic factors may contribute to up to 25% of breast cancer in women under 30.

Baylor Genetics is committed to helping providers uncover hereditary risks earlier and guide patients toward proactive care. Our hereditary cancer tests, including the Comprehensive Hereditary Cancer Panel and BRCA1 & BRCA2 Panel, deliver critical insights that support informed decision making.

Visit our oncology hereditary cancer test options to learn more: https://catalog.baylorgenetics.com/category/oncology

Baylor Genetics' RNA Sequencing (RNAseq) has been named a Quarterfinalist in the 2025 Digital Health Hub Foundation Digi...
09/29/2025

Baylor Genetics' RNA Sequencing (RNAseq) has been named a Quarterfinalist in the 2025 Digital Health Hub Foundation Digital Health Awards for Best-in-Class Clinical Diagnostic Device!​​

This recognition highlights innovations that are transforming healthcare, and most importantly, improving patients’ lives. Our RNAseq helps resolve uncertain findings from exome and genome sequencing and detects splice variants with direct clinical relevance. By providing clearer answers, RNAseq empowers clinicians with the insights they need to guide care and improve outcomes.

At Baylor Genetics, every advancement is driven by our commitment to patients and families, and we’re proud to see that work recognized on a national stage.​​

Baylor Genetics is seeking a Senior Product Owner of Pharmacogenomics to lead the evolution of our PGx testing portfolio...
09/26/2025

Baylor Genetics is seeking a Senior Product Owner of Pharmacogenomics to lead the evolution of our PGx testing portfolio and digital solutions.​

In this role, you will lead the vision and roadmap for PGx, turning complex scientific and regulatory needs into innovative solutions that advance reporting and decision-support. Working across R&D, operations, and commercial teams, you will also help shape products that deliver real clinical impact.​

Your leadership will help deliver tools that improve patient outcomes. Apply today: https://recruiting2.ultipro.com/BAY1006BML/JobBoard/0669eed3-5441-4f8e-a7b1-c5df596a4dfe/OpportunityDetail?opportunityId=0c4a0360-9857-452e-b772-b01217d3ff4e ​

When your patients have unexplained symptoms, genetic testing is often the first step toward answers. But what happens i...
09/25/2025

When your patients have unexplained symptoms, genetic testing is often the first step toward answers. But what happens if those results are inconclusive? In many cases, there’s still hope. ​

RNA sequencing (RNAseq) can examine how genetic variants affect gene function. By providing this additional layer of insight, RNAseq can bring clarity to complex cases, shorten the diagnostic odyssey, and help guide diagnosis and treatment decisions.​

Baylor Genetics is committed to helping patients find answers. Stay tuned for the upcoming RNAseq deep-dive podcast episode with DNA Today and Christine Eng, MD.

Learn more: https://www.baylorgenetics.com/blog/unlocking-comprehensive-genetic-insights-with-rnaseq-for-wgs-and-wes/

09/24/2025

Meet Romy Fawaz, MS, CGC, Genetic Counselor at Baylor Genetics! ​

​Romy is passionate about working with providers and patients to support every stage of the genetic testing process. Her expertise helps in educating providers on testing options and supporting patients through their medical histories. ​

We are grateful for Romy’s hard work as she supports providers, giving them the confidence to make informed decisions and deliver the best possible care for their patients. ​

Some genetic changes, called Short Tandem Repeats (STRs), are linked to certain neurological conditions but they can be ...
09/23/2025

Some genetic changes, called Short Tandem Repeats (STRs), are linked to certain neurological conditions but they can be tough to find with standard tests. Even advanced tools like Whole Genome Sequencing (WGS) may miss them.​

That’s why Baylor Genetics combines WGS with specialized STR testing for 29 different conditions. This approach gives doctors a clearer picture, helping families get answers faster and guiding the right care sooner. ​

Learn more: www.baylorgenetics.com ​

Baylor Genetics is seeking a Brand Manager to help strengthen and guide the evolution of our brand.In this role, you wil...
09/19/2025

Baylor Genetics is seeking a Brand Manager to help strengthen and guide the evolution of our brand.

In this role, you will lead the brand strategy, develop omni-channel campaigns, and manage brand consistency during change. Your work will play a key role in how we connect with patients, providers, and partners.

If you are a strategic thinker with a passion for building and maintaining brand integrity, we encourage you to join our team! Apply today: https://recruiting2.ultipro.com/BAY1006BML/JobBoard/0669eed3-5441-4f8e-a7b1-c5df596a4dfe/OpportunityDetail?opportunityId=41d9773c-6d44-44f4-a440-4b2a69840913

We’re proud to share that our Chief Medical Officer and Chief Quality Officer, Dr. Christine Eng, has been named 2025 Wo...
09/18/2025

We’re proud to share that our Chief Medical Officer and Chief Quality Officer, Dr. Christine Eng, has been named 2025 Woman Scientist of the Year in the Stevie® Awards for Women in Business!​

This global recognition honors women who are breaking new ground in scientific research and innovation. Dr. Eng’s leadership has been instrumental in advancing the integration of genomics into clinical practice, championing scientific excellence, and driving our mission to end the diagnostic odyssey for patients and their families.​

Please join us in congratulating Dr. Eng on this well-deserved honor.​

Learn more about the Stevie® Awards for Women in Business: https://www.baylorgenetics.com/news/baylor-genetics-cmo-christine-eng-woman-scientist-year-2025-stevie-award/

In his Fast Company byline, Kengo Takishima, Chairman & CEO of Baylor Genetics, makes a compelling case for why genomic ...
09/16/2025

In his Fast Company byline, Kengo Takishima, Chairman & CEO of Baylor Genetics, makes a compelling case for why genomic sequencing should become the standard of care.

Families need answers faster, and genomic sequencing can help provide that. The Sunshine Genetics Act in Florida and the American Academy of Pediatrics’ new guidance recommend genome and exome sequencing as first-tier tests, emphasizes the growing need.

At Baylor Genetics, we see firsthand the life-changing impact genomic sequencing makes on pediatric care. It improves outcomes, reduces long-term costs, and renews hope for families navigating rare diseases.

Read our CEO’s perspective on how genomic sequencing can transform the diagnostic odyssey: https://www.fastcompany.com/91402158/heres-why-genomic-sequencing-should-be-a-standard-of-care

RNA sequencing and multi-omic approaches are transforming diagnosis and care for patients with rare diseases. Last week ...
09/15/2025

RNA sequencing and multi-omic approaches are transforming diagnosis and care for patients with rare diseases. Last week at , Christine Eng, MD, our Chief Medical Officer, joined Kira Dineen, the host of the award-winning DNA Today podcast, to discuss the future of precision diagnostics.

The podcast showcases some of the most influential voices in genomics, and we’re proud to have Dr. Eng featured alongside other thought leaders shaping the future of the diagnostic field. Watch the AGBT recap and reflections video on DNA Today’s website, and stay tuned for the upcoming RNAseq deep-dive episode with Dr. Eng in the weeks ahead: https://dnapodcast.com/episodes/2025/9/12/358-agbt-precision-health-2025-meeting-recaps-and-reflections

09/15/2025

Today is the start of ! Mitochondrial diseases are often misunderstood since they can cause a wide range of symptoms. For individuals living with a mitochondrial disease, the effects can be overwhelming.

In this video, Dr. Xueyang Pan presents research that shows how low levels of mitochondrial DNA mutations, which were once considered insignificant, can drive serious clinical symptoms in patients with single large-scale mitochondrial DNA deletion syndromes.

Baylor Genetics is committed to advocating for awareness, treatment, and support for people who are impacted by these conditions.

Learn more: https://youtu.be/hjqmU7w7Zkc?si=EhxE3ORkcq-qnjyG

Address

2450 Holcombe Boulevard
Houston, TX
77021

Opening Hours

Monday 8am - 6pm
Tuesday 8am - 6pm
Wednesday 8am - 6pm
Thursday 8am - 6pm
Friday 8am - 6pm
Saturday 8am - 6pm

Telephone

+18004114363

Website

Alerts

Be the first to know and let us send you an email when Baylor Genetics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Our Story

Baylor Genetics is a joint venture of Miraca Holdings, Inc. and Baylor College of Medicine, including the #1 NIH-funded Department of Molecular and Human Genetics. A pioneer of precision medicine for nearly 40 years, Baylor Genetics now offers a full spectrum of clinically relevant genetic testing, access to world-renowned experts, and the confidence to provide patients with the best care.

Baylor Genetics, located in Houston’s Texas Medical Center, serves clients in 50 states and 16 countries.